The maker’s programs

Eversense PASS Program

Savings card from Senseonics

With commercial insurance $199 or less for the one-year sensor and transmitter

Commercial insurance only; the program pays at most $2,500 per purchase and does not cover the insertion and removal procedures. Not for Medicare, Medicaid or TRICARE.

See it on eversensecgm.com 

In the maker’s words

“Patient must pay up to $199 for their Eversense® 365 Sensor and Transmitter.”

From the maker’s page on eversensecgm.com, checked November 17, 2026.

Eversense 365 cash-pay options

Maker’s price from Senseonics

Without insurance. Its page doesn’t list a dollar amount.

The price is given by phone only: call 844-736-7348 (844-SENSE4U) to talk through cash-pay options.

See it on eversensecgm.com 

In the maker’s words

“For individuals without insurance, we offer cash-pay options that provide more clarity on the full cost upfront rather than ongoing monthly supply costs.”

From the maker’s page on eversensecgm.com, checked November 17, 2026.

From Senseonics’s own website, in its own words. DrugAlt reads each page again every week.

More ways to pay less

What it is

A sensor implanted under the skin, with a body-worn transmitter, that reads glucose (sugar) around the clock and sends it to a phone app.

Used for: Tracking glucose (sugar) levels in diabetes; Spotting episodes of high and low glucose (sugar); Sending glucose readings to connected devices, including systems that adjust insulin automatically.

In the FDA’s records’ words

Implantable glucose monitoring system transmitter. A body-worn, battery-powered component of an implantable glucose monitoring system designed to wirelessly transmit glucose measurements continuously from the implanted sensor to a receiver (e.g., a mobile device). This is a reusable device.

Integrated Continuous Glucose Monitoring System With Sensor Containing Dexamethasone Acetate. An integrated continuous glucose monitoring system (iCGM) with sensor containing dexamethasone acetate is intended to automatically measure glucose in bodily fluids continuously or frequently for a specified period of time. iCGM systems are designed to reliably and securely transmit glucose measurement data to digitally connected devices, including automated insulin dosing systems, and are intended to be used alone or in conjunction with these digitally connected medical devices for the purpose of managing a disease or condition related to glycemic control. The dexamethasone acetate coating is intended to reduce inflammation at the sensor insertion site.

Only your prescriber can say whether a device is right for you.

In the FDA’s device database

11 versions sold now

Each opens its FDA record. The model number is on the box.

Show all 11

Source: the FDA’s device database (GUDID), November 2, 2026.

Similar devices

All 9 continuous glucose monitors